| 5NI5: reference: Structure-based design leads to potent and orally bioavailable inverse agonists of RORgammat., Narjes F, Xue Y, von Berg S, Malmberg J, Llinas A, Olsson RI, Jirholt J, Grindebacke H, Leffler A, Hossain N, Lepisto M, Thunberg L, Leek H, Aagaard A, McPheat J, Hansson EL, Back E, Tangefjord S, Chen R, Xiong Y, Hongbin G, Hansson T, J Med Chem. 2018 Aug 10. doi: 10.1021/acs.jmedchem.8b00783. PMID: 30095900 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).